CL2024000373A1 - Compuesto inductor de la degradación de plk1 novedoso - Google Patents
Compuesto inductor de la degradación de plk1 novedosoInfo
- Publication number
- CL2024000373A1 CL2024000373A1 CL2024000373A CL2024000373A CL2024000373A1 CL 2024000373 A1 CL2024000373 A1 CL 2024000373A1 CL 2024000373 A CL2024000373 A CL 2024000373A CL 2024000373 A CL2024000373 A CL 2024000373A CL 2024000373 A1 CL2024000373 A1 CL 2024000373A1
- Authority
- CL
- Chile
- Prior art keywords
- plk1
- degradation
- novel
- inducing compound
- present disclosure
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000015556 catabolic process Effects 0.000 title abstract 3
- 238000006731 degradation reaction Methods 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title abstract 3
- 101150073897 plk1 gene Proteins 0.000 title 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 abstract 3
- 108010056274 polo-like kinase 1 Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente divulgación se refiere a un compuesto inductor de la degradación de PLK1 novedoso, a un método para preparar el mismo y al uso del mismo. Los compuestos de la presente divulgación exhiben un efecto de inducción de la degradación de PLK1. Por lo tanto, los compuestos de la presente divulgación pueden utilizarse eficazmente para prevenir o tratar enfermedades relacionadas con PLK1.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210105358 | 2021-08-10 | ||
| KR20210106488 | 2021-08-12 | ||
| KR20210117389 | 2021-09-03 | ||
| KR20210126757 | 2021-09-24 | ||
| KR20220008456 | 2022-01-20 | ||
| KR20220020996 | 2022-02-17 | ||
| KR20220054880 | 2022-05-03 | ||
| KR20220075838 | 2022-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000373A1 true CL2024000373A1 (es) | 2024-07-19 |
Family
ID=85200656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000373A CL2024000373A1 (es) | 2021-08-10 | 2024-02-06 | Compuesto inductor de la degradación de plk1 novedoso |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US11912710B2 (es) |
| EP (4) | EP4384521A4 (es) |
| JP (4) | JP2024530495A (es) |
| KR (5) | KR102604801B1 (es) |
| CN (2) | CN116322700B (es) |
| AU (1) | AU2022327025A1 (es) |
| CA (1) | CA3228601A1 (es) |
| CL (1) | CL2024000373A1 (es) |
| CO (1) | CO2024001256A2 (es) |
| CR (1) | CR20240120A (es) |
| EC (1) | ECSP24010109A (es) |
| IL (1) | IL310678A (es) |
| MX (1) | MX2024001774A (es) |
| PE (1) | PE20240894A1 (es) |
| WO (5) | WO2023018237A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021194318A1 (en) * | 2020-03-27 | 2021-09-30 | Uppthera | Plk1 selective degradation inducing compound |
| KR20250037591A (ko) * | 2023-02-02 | 2025-03-17 | (주) 업테라 | 신규 plk1 분해 유도 화합물 |
| CN118946561A (zh) * | 2023-03-10 | 2024-11-12 | 标新生物医药科技(上海)有限公司 | 新颖的e3泛素连接酶配体、蛋白降解剂及其应用 |
| WO2024254532A1 (en) | 2023-06-08 | 2024-12-12 | Nurix Therapeutics, Inc. | Bifunctional azines conjogates as selective degraders of smarca2 and therapeutic uses thereof |
| CN117126133A (zh) * | 2023-08-14 | 2023-11-28 | 中国海洋大学 | 一种化合物及其用途 |
| WO2025062330A1 (en) | 2023-09-20 | 2025-03-27 | Aurigene Oncology Limited | Heterocyclic compounds as cbp selective degraders |
| WO2025125575A1 (en) | 2023-12-14 | 2025-06-19 | Astrazeneca Ab | Irak4 protacs |
| WO2025239662A1 (ko) * | 2024-05-13 | 2025-11-20 | (주) 업테라 | 분해 약물-항체 접합체용 plk1 분해 유도 화합물 |
| CN118724841A (zh) * | 2024-06-14 | 2024-10-01 | 南通华祥医药科技有限公司 | 一种n-氨基哌啶二盐酸盐的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2649324A1 (en) * | 2006-04-12 | 2007-10-25 | Jean-Damien Charrier | Tetrahydropteridines useful as inhibitors of protein kinases |
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| KR101157848B1 (ko) | 2007-03-22 | 2012-07-11 | 다케다 야쿠힌 고교 가부시키가이샤 | Ｐｌｋ１ 저해제로서 유용한 치환된 피리미도디아제핀 |
| JP2011527667A (ja) | 2008-06-18 | 2011-11-04 | 武田薬品工業株式会社 | ハロ置換ピリミドジアゼピン |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017079267A1 (en) * | 2015-11-02 | 2017-05-11 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| CN106543185B (zh) * | 2016-11-10 | 2017-12-15 | 吉林大学 | 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| CA3050309A1 (en) * | 2017-01-31 | 2018-08-09 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN106977584B (zh) * | 2017-04-19 | 2019-12-06 | 吉林大学 | 靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| WO2020023851A1 (en) | 2018-07-26 | 2020-01-30 | Yale University | Bifunctional substitued pyrimidines as modulators of fak proteolyse |
| CN111018857B (zh) * | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| CN109879877B (zh) * | 2019-03-04 | 2021-08-10 | 吉林大学 | 一种可降解plk1和brd4蛋白的化合物及其应用 |
| WO2021053495A1 (en) | 2019-09-16 | 2021-03-25 | Novartis Ag | Bifunctional degraders and their methods of use |
| AU2020356484A1 (en) * | 2019-09-27 | 2022-03-17 | Dana-Farber Cancer Institute, Inc. | ERK5 degraders as therapeutics in cancer and inflammatory diseases |
| WO2021194318A1 (en) * | 2020-03-27 | 2021-09-30 | Uppthera | Plk1 selective degradation inducing compound |
-
2022
- 2022-08-10 JP JP2024507883A patent/JP2024530495A/ja active Pending
- 2022-08-10 EP EP22856233.6A patent/EP4384521A4/en active Pending
- 2022-08-10 WO PCT/KR2022/011962 patent/WO2023018237A1/en not_active Ceased
- 2022-08-10 EP EP22808930.6A patent/EP4157849A4/en active Pending
- 2022-08-10 JP JP2023514149A patent/JP7555155B2/ja active Active
- 2022-08-10 KR KR1020227036557A patent/KR102604801B1/ko active Active
- 2022-08-10 US US18/019,047 patent/US11912710B2/en active Active
- 2022-08-10 JP JP2024507884A patent/JP2024530195A/ja active Pending
- 2022-08-10 PE PE2024000208A patent/PE20240894A1/es unknown
- 2022-08-10 KR KR1020227046443A patent/KR102662205B1/ko active Active
- 2022-08-10 WO PCT/IB2022/057471 patent/WO2023017442A1/en not_active Ceased
- 2022-08-10 WO PCT/KR2022/011961 patent/WO2023018236A1/en not_active Ceased
- 2022-08-10 CN CN202280006505.1A patent/CN116322700B/zh active Active
- 2022-08-10 US US18/580,506 patent/US20250101025A1/en active Pending
- 2022-08-10 KR KR1020247013823A patent/KR20240060721A/ko active Pending
- 2022-08-10 US US18/580,553 patent/US20250114460A1/en active Pending
- 2022-08-10 CN CN202280006544.1A patent/CN116261458B/zh active Active
- 2022-08-10 IL IL310678A patent/IL310678A/en unknown
- 2022-08-10 KR KR1020227036596A patent/KR102604802B1/ko active Active
- 2022-08-10 EP EP22808931.4A patent/EP4157850A4/en active Pending
- 2022-08-10 CA CA3228601A patent/CA3228601A1/en active Pending
- 2022-08-10 KR KR1020227042318A patent/KR102604803B1/ko active Active
- 2022-08-10 CR CR20240120A patent/CR20240120A/es unknown
- 2022-08-10 EP EP22855629.6A patent/EP4384520A4/en active Pending
- 2022-08-10 WO PCT/IB2022/057475 patent/WO2023017446A1/en not_active Ceased
- 2022-08-10 AU AU2022327025A patent/AU2022327025A1/en active Pending
- 2022-08-10 JP JP2023514160A patent/JP7555156B2/ja active Active
- 2022-08-10 US US18/019,034 patent/US11939334B2/en active Active
- 2022-08-10 WO PCT/KR2022/011963 patent/WO2023018238A1/en not_active Ceased
- 2022-08-10 MX MX2024001774A patent/MX2024001774A/es unknown
-
2024
- 2024-02-06 CL CL2024000373A patent/CL2024000373A1/es unknown
- 2024-02-06 CO CONC2024/0001256A patent/CO2024001256A2/es unknown
- 2024-02-07 EC ECSENADI202410109A patent/ECSP24010109A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000373A1 (es) | Compuesto inductor de la degradación de plk1 novedoso | |
| CL2022003434A1 (es) | Compuestos para tratar la enfermedad de huntington (divisional solicitud 202003378) | |
| CO2021016594A2 (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
| CO2017009891A2 (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| MX2021013854A (es) | Compuestos para tratar enfermedad de huntington. | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| CO2020006523A2 (es) | Compuestos moduladores de sting y métodos de elaboración y uso | |
| MX2019014514A (es) | Compuestos para tratar la enfermedad de huntington. | |
| PE20191496A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CR20160558A (es) | Compuesto de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| CO2019011604A2 (es) | Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos | |
| MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| CL2024000250A1 (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington | |
| MX2021002215A (es) | Derivados de tetrahidropiridopirimidina como moduladores de ahr. | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| ECSP21011232A (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende | |
| CL2020002217A1 (es) | Uso de alcoxipirazoles como inhibidores de la nitrificación | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| MX2018014080A (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| CO2021011023A2 (es) | Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos | |
| AR117834A1 (es) | Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisoméricamente enriquecido y método de síntesis |